The International Randomized Study of Interferon and STI571 (IRIS) study prospectively
compared imatinib with interferon-alpha/low-dose cytarabine (IFN/LDAC) in 1,106 newly …

In this article, the authors briefly recap the key clinical trials that involve imatinib mesylate
(Gleevec, Glivec, STI571). Because the reader may be familiar with many of these …

Imatinib mesylate is a relatively new drug that targets the BCR-ABL chimeric protein, the
molecular basis of chronic myeloid leukemia (CML). A phase II clinical trial in 39 Japanese …

Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia
(CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This …

There are few publications on responses of patients with chronic phase chronic myeloid
leukemia (CP-CML) from the Indian sub continent to imatinib mesylate (IM). This study …

Imatinib is clearly an important contribution to the management of patients with chronic
myeloid leukemia (CML). Based on the available data, it seems reasonable to conclude that …

6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …

Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …

The results of imatinib (Gleevec)(formerly STI571) therapy for chronic myeloid leukemia
(CML) have continued to improve and have surpassed almost everyone's predictions …

BACKGROUND There is paucity of data from developing countries on the efficacy and safety
of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study …